Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Equities researchers at Zacks Research cut their Q2 2025 earnings per share estimates for shares of Avanos Medical in a research note issued to investors on Tuesday, May 27th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.18 per share for the quarter, down from their previous estimate of $0.26. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical's Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.29 EPS, Q2 2026 earnings at $0.24 EPS, Q3 2026 earnings at $0.30 EPS, Q4 2026 earnings at $0.38 EPS, FY2026 earnings at $1.16 EPS and FY2027 earnings at $1.34 EPS.
Separately, Wall Street Zen upgraded Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.
Check Out Our Latest Research Report on Avanos Medical
Avanos Medical Stock Down 2.7%
Shares of Avanos Medical stock traded down $0.34 on Thursday, reaching $12.23. 150,106 shares of the company were exchanged, compared to its average volume of 364,452. Avanos Medical has a one year low of $11.84 and a one year high of $25.36. The company has a market capitalization of $565.75 million, a price-to-earnings ratio of 35.96 and a beta of 1.13. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average of $12.81 and a 200 day moving average of $15.19.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The company had revenue of $167.50 million for the quarter, compared to analysts' expectations of $161.75 million. During the same quarter in the prior year, the business posted $0.22 EPS. The business's revenue was up .8% compared to the same quarter last year.
Institutional Investors Weigh In On Avanos Medical
Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new stake in Avanos Medical in the 4th quarter valued at $64,000. State of Wyoming grew its holdings in Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company's stock valued at $82,000 after buying an additional 2,923 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Avanos Medical by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock valued at $129,000 after buying an additional 6,714 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in Avanos Medical by 14.6% in the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company's stock valued at $161,000 after buying an additional 1,289 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new position in Avanos Medical in the 1st quarter valued at $146,000. Institutional investors own 95.17% of the company's stock.
Insider Buying and Selling
In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares in the company, valued at approximately $1,251,216.75. This represents a 7.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is currently owned by corporate insiders.
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Read More
Before you consider AVANOS MEDICAL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVANOS MEDICAL wasn't on the list.
While AVANOS MEDICAL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
